VTGN VistaGen Therapeutics Inc
VTGN Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
57
Frequently Asked Questions
What is Market Cap of Vistagen Therapeutics Inc.?
What is the 52-week high for Vistagen Therapeutics Inc.?
What is the 52-week low for Vistagen Therapeutics Inc.?
What is Vistagen Therapeutics Inc. stock price today?
What was Vistagen Therapeutics Inc. stock price yesterday?
What is the PE ratio of Vistagen Therapeutics Inc.?
What is the Price-to-Book ratio of Vistagen Therapeutics Inc.?
What is the 50-day moving average of Vistagen Therapeutics Inc.?
How many employess does Vistagen Therapeutics Inc. has?